Advanced Filters
noise

Lymphocytic Leukemia, Acute Clinical Trials

A listing of Lymphocytic Leukemia, Acute medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 498 clinical trials
M Marlise Luskin, MD, MSCE

Venetoclax Plus Inotuzumab for B-ALL

This research study is evaluating the safety and efficacy of administering venetoclax and inotuzumab ozogamicin in combination in patients with acute lymphoblastic leukemia (ALL) The names of the study drugs involved in this study are: Venetoclax Inotuzumab ozogamicin Dexamethasone

18 years of age All Phase 1
Y Yanjie He, Doctor

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

The main purpose of this study is to verify the safety and potential effectiveness of CART cells combined with peptide specific dendritic cell in relapsed/refractory leukemia.

18 - 80 years of age All Phase 1
M Mari Dallas

Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia

The survival of children, adolescents and young adults (AYA) with acute leukemia has improved dramatically over the last two decades. This success is a result of using multiple chemotherapy drugs in combination, with the inclusion of drugs that enter the brain and prevent leukemia cells from growing there. Studies in …

- 30 years of age All Phase N/A
D Demetra Christou, PhD

All-extremity Exercise During Breast Cancer Chemotherapy

Currently, there are 3.5 million breast cancer survivors in the United States and this number is expected to increase dramatically. The proposed research will examine whether a novel exercise intervention for breast cancer patients who are undergoing chemotherapy protects against cardiovascular dysfunction. Findings may have implications for cardiovascular disease prevention …

18 - 85 years of age Female Phase N/A
C Claire White

CD22 Redirected Autologous T Cells for ALL

This is a single center, single arm, open-label pilot study to determine the feasibility and safety of a single dose administered as spilt fractions of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART22" cells) in pediatric patients with …

1 - 29 years of age All Phase 1
D Dong Qian, M.D.

Radiotherapy to All Residual Lesions After Chemoimmunotherapy

Extensive-stage small-cell lung cancer is a lethal malignancy with an extremely poor prognosis. First-line chemotherapy could only achieve an overall survival of approximately 10 months. CREST study demonstrated that the addition of thoracic radiotherapy to the patients who responded to chemotherapy could increase the 2-year survival rate from 3% to …

18 - 70 years of age All Phase 1/2
M Melissa Hines, MD

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come back after treatment (relapse). Primary Objective To determine the safety and maximum tolerated dose of intravenous …

- 21 years of age All Phase 1
J Jin Jie

VHAG in Treating R/R T-ALL/LBL

Acute T cell lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive type of leukemia that results from the malignant evolution of T-lineage progenitor cells at different differentiation stages. After induction chemotherapy and consolidation chemotherapy, there are still about 30% of patients who cannot achieve complete remission of clinical symptoms or negative MRD. …

14 - 74 years of age All Phase 2
L Lung-Ji Chang, Ph.D

NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

The purpose of this study is to determine the feasibility, safety, and efficacy of a combination therapy in the treatment of B-cell acute lymphoblastic leukemia (B-ALL) based on multi-antigen-targeted chimeric antigen receptor T cells (CAR-T) followed by engineered immune effector cytotoxic T lymphocytes (CTLs) and immune-modified dendritic cell vaccine (DCvac). …

6 - 65 years of age All Phase 1
D Dmitry Balashov, MD, PhD

Evaluation of Brain Changes in ALL Patients on Therapy

The study is aimed at assessing changes in the brain of patients from 6 to 18 years old with a diagnosis of acute lymphoblastic leukemia during chemotherapy.

6 - 18 years of age All Phase N/A

Simplify language using AI